Fig. 2.
Genetically modified lymphocytes express the introduced CD19-specific chimeric immunoreceptor and are differentiated effector T cells.
(A) Western blot result from reduced whole T-cell lysates probed with an anti–CD3-ζ mAb. The unmodified T-cell line (lane 1) and representative genetically modified T-cell clones (lanes 2 and 3) each display a 21-kDa band consistent with the wild-type ζ chain. In addition, the 2 hygromycin-resistant T-cell clones demonstrate a second band of approximately 66 kDa consistent with the introduced chimeric ζ chain. (B) Phenotype of a CD19-specific T-cell clone using flow cytometry. Binding of specific mAbs (bold lines) is relative to isotype control (dotted lines), and the percentage of cells in the M2 gate is indicated.